Expected Decrease in Potassium with Lokelma (Sodium Zirconium Cyclosilicate)

Mechanism of Action and Onset

• The American College of Cardiology recommends Sodium zirconium cyclosilicate (SZC) as a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium ions in the gastrointestinal tract, contributing to its faster onset of action, unlike other potassium binders, SZC works in both the small and large intestines 1

Evidence for Potassium Reduction

• The standard initial treatment protocol of 10g three times daily for 48 hours consistently demonstrates a mean change of 1.1 mEq/L in serum potassium reduction, as seen in the HARMONIZE trial, with a reduction from 5.6 mEq/L to 4.5 mEq/L 2
• A 20g dose administered as 10g twice daily would be expected to produce a slightly lower but still significant potassium reduction, with clinical trials demonstrating a dose-dependent response with SZC 2, 3

Dose-Response Relationship

• Clinical trials have demonstrated a dose-dependent response with SZC, with increasing effectiveness at higher doses, including an exponential rate of change in mean serum K+ at 48 hours, with 0.11% reduction with SZC 1.25g, 0.16% with SZC 2.5g, 0.21% with SZC 5g, and 0.30% with SZC 10g 2, 4

Clinical Considerations and Monitoring

• Potassium reduction may vary based on baseline potassium levels, with greater reductions typically seen in patients with higher initial potassium levels, highlighting the importance of regular monitoring of serum potassium to avoid hypokalemia 2

Comparison to Other Potassium Binders

• SZC is more selective for potassium than other binders like sodium polystyrene sulfonate (SPS) and patiromer, with a faster onset of action (1 hour) compared to patiromer (7 hours) 1

Lokelma Dosing and Efficacy for Hyperkalemia

Initial Treatment Phase

• The American Heart Association recommends administering 10 g of Lokelma three times daily for up to 48 hours to effectively reduce serum potassium levels, with a mean reduction of 1.1 mEq/L in patients with hyperkalemia 5, 6
• Onset of action begins within 1 hour of administration for patients with severe hyperkalemia (≥6.0 mEq/L), as reported by the Mayo Clinic Proceedings 7

Maintenance Treatment Phase

• Clinical trials showed that maintenance doses of 5 g, 10 g, and 15 g once daily effectively maintained normal potassium levels (3.5-5.0 mEq/L) for up to 28 days, according to the Mayo Clinic Proceedings 5, 8

Common Side Effects and Precautions

• The most common adverse effect is mild to moderate edema, particularly with higher doses (15 g daily), as reported by the Mayo Clinic Proceedings 7

Lokelma Dosing for Hyperkalemia

Pharmacological Properties

• Lokelma has a faster onset of action, beginning within 1 hour, compared to other potassium binders like patiromer, which takes 7 hours 9
• Lokelma is highly selective for potassium compared to other binders like sodium polystyrene sulfonate (SPS), and works in both small and large intestines, contributing to its faster onset of action 9
• Lokelma has a more favorable side effect profile than SPS, which has been associated with serious gastrointestinal adverse events 9

Lokelma Dosing and Management for Hyperkalemia

Expected Outcomes and Safety

• In clinical trials, 90% of patients maintained normokalemia on 10 g daily dosing over 28 days, according to the Mayo Clinic Proceedings 10
• The dose-dependent response shows 0.30% exponential rate of change with 10 g dosing, which is the most effective studied dose, as reported in the Mayo Clinic Proceedings 11
• Edema is the most common adverse effect, occurring in approximately 6% of patients on 10 g daily, compared to 14% on 15 g daily, as noted in the Mayo Clinic Proceedings 10

Clinical Context and Treatment

• At 5.8 mEq/L, this represents moderate hyperkalemia that warrants treatment but is not immediately life-threatening, as stated in the Mayo Clinic Proceedings 12
• Do not discontinue RAAS inhibitors if the patient is taking them; instead, manage the hyperkalemia with Lokelma while maintaining cardioprotective therapy, as recommended by the Mayo Clinic Proceedings 13 and 14
• Do not prematurely discontinue cardioprotective medications like ACE inhibitors or ARBs; the newer potassium binders like Lokelma enable optimization of RAAS inhibitor therapy, as noted in the Mayo Clinic Proceedings 13 and 10

Lokelma Dosing Guidelines

Dose-Response Relationship

• The efficacy of Lokelma is clearly dose-dependent, with a 10 g dose having the most effective studied rate of change of 0.30% 15

Contraindications and Precautions

• The American Heart Association recommends monitoring for edema in patients who should restrict sodium intake or are prone to fluid overload, as each 5 g dose contains approximately 400 mg of sodium 15

Lokelma Efficacy and Safety in Hyperkalemia Management

Dose-Response Relationship

• The efficacy of Lokelma is clearly dose-dependent, with a 0.21% rate of change in serum K+ at 48 hours with a 5 g dose, and a 0.30% rate of change with a 10 g dose, which is the most effective studied dose 16
• All doses ≥2.5 g showed P<.001 versus placebo, indicating a significant reduction in serum potassium levels 16
• A dose of 2.5 g has a 0.16% rate of change in serum K+ at 48 hours 17

Monitoring Protocol

• Check serum potassium within 2-4 weeks after initiation or dose adjustment, and decrease the dose or discontinue if serum potassium falls below the desired target range 18
• The reversible decrease in eGFR on initiation is generally not an indication to discontinue therapy, according to the Kidney International guidelines 18

Advantages Over Older Potassium Binders

• Lokelma is more selective for potassium than sodium polystyrene sulfonate (SPS), which reduces the risk of serious gastrointestinal adverse events, as recommended by the Mayo Clinic Proceedings 17
• Unlike SPS, Lokelma does not cause hypocalcemia or hypomagnesemia due to its selective binding properties, as reported in the Mayo Clinic Proceedings 17

Lokelma Dosing and Efficacy

Initial Treatment Phase

• The American Heart Association recommends reducing serum potassium within 1 hour of the first dose, with Lokelma achieving this reduction 19

Long-Term Use

• The National Kidney Foundation suggests that Lokelma can be used continuously for extended periods, with efficacy and safety demonstrated for up to 11-12 months, and 88% of patients maintaining mean serum potassium ≤5.1 mEq/L throughout the study period 19

Lokelma (Sodium Zirconium Cyclosilicate) – Evidence‑Based Dosing and Outcomes

Acute Efficacy and Onset

Maintenance Dosing and Short‑Term Control

Long‑Term Efficacy

Safety Profile

Metabolic Benefits